Asciminib Elicits Safe and Durable Responses in Previously Treated CML
December 12th 2023Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.
Read More